Skip to main content
. 2016 Mar 23;21(5):539–546. doi: 10.1634/theoncologist.2015-0349

Figure 2.

Figure 2.

Mean changes from baseline in outcome measures by persistence. (A): EuroQOL VAS. Positive mean change in quality of life indicates improvement from baseline. Mean (±SD) baseline EuroQOL scores: persistent, 83.9 ± 12.14; not persistent, 84.8 ± 12.58 (p = .21). p value by Wilcoxon test. ∗, Statistically significant. QOL VAS range, 0–100 (100 indicating best imaginable health state). (B): CESD. Positive mean change in CES-D indicates improvement from baseline. Mean baseline CES-D scores: persistent, 7.5 ± 6.73; not persistent, 9.2 ± 8.10; p = .036. p value by Wilcoxon test; ∗, Statistically significant. CESD range, 0–60 (≥16 suggests clinical depression). (C): HADSA. Positive mean change in HADSA indicates improvement from baseline. Mean baseline HADS-A scores: persistent, 3.90 ± 3.03; not persistent, 4.4 ± 3.28; p = .11. p value by Wilcoxon test. HADSA range, 0–21 (≥8 suggests clinical anxiety). (D): MSK symptom cluster. Positive mean change in MSK symptom cluster indicates worse from baseline. Mean baseline MSK symptom cluster scores: persistent, 0.51 ± 0.049; not persistent, 0.62 ± 0.53; p = .012. p value by Wilcoxon test. ∗, Statistically significant. MSK symptom cluster range, 0–4.

Abbreviations: CESD, Centers for Epidemiologic Studies–Depression; HADSA, anxiety scale of the Hospital Anxiety and Depression Scale; MSK, musculoskeletal; VAS, Visual Analog Scale.